Navigation Links
Tolerx Presents Data at 69th Scientific Sessions of the American Diabetes Association
Date:6/8/2009

About Otelixizumab

Otelixizumab is a novel monoclonal antibody being developed for the treatment of type 1 diabetes and other autoimmune diseases. Otelixizumab targets CD3, a T lymphocyte receptor involved in normal cell signaling. Otelixizumab has not yet been approved for marketing. Data suggest that the antibody may work in patients with type 1 diabetes who have residual beta cells by blocking the function of effector T cells that mistakenly attack and destroy insulin-producing beta cells, while stimulating regulatory T cells that are understood to protect against effector T cell damage, thus preserving the beta cells' ability to make insulin.

About Tolerx

Tolerx is a biopharmaceutical company engaged in the discovery and development of novel therapies for immune-mediated diseases. The company's pipeline includes its lead candidate, otelixizumab, an anti-CD3 monoclonal antibody partnered with GlaxoSmithKline in Phase 3 development for the treatment of type 1 diabetes; a Phase 1 candidate, MTRX1011A, an anti-CD4 antibody that is being developed in collaboration with Genentech, Inc. for the treatment of autoimmune indications; and two pre-clinical candidates, TRX518 and TRX385, that enhance immune responses and are being evaluated for potential benefit in the treatment of cancer, chronic viral diseases, and as vaccine adjuvants. Tolerx is a privately held company headquartered in Cambridge, MA USA. For more information, please visit www.tolerx.com.


'/>"/>
SOURCE TolerRx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Tolerx Initiates Dosing of Otelixizumab, a Novel Type 1 Diabetes Agent, in DEFEND, a Phase 3 Clinical Trial
2. Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial
3. Tolerx Advancing Novel Type 1 Diabetes Agent into Phase III Clinical Trial Program Following End of Phase II FDA Meeting
4. Tolerx Achieves Milestone with Completion of Phase Ib Clinical Study of TRX1 in Cutaneous Lupus Erythematosus
5. Micromet Presents Update on Blinatumomabs Response Rate and Duration in a Phase 1 Study in Non-Hodgkins Lymphoma Patients
6. Proteolix Presents Positive Clinical Data for Carfilzomib in Multiple Myeloma at the 2009 ASCO Annual Meeting
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Proteolix Presents Phase 1b/2 Clinical Data for Carfilzomib in Advanced Solid Tumor Patients at the 2009 ASCO Annual Meeting
9. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
10. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
11. Paloma Pharmaceuticals Presents at the Association for Research in Vision and Ophthalmology 2009 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Mass. , Dec. 22, 2014 ... leading manufacturer of innovative dialysis products, announced today ... has cleared its System One™ to perform hemodialysis ... known as home nocturnal hemodialysis. NxStage,s® System One ... by the FDA for this indication. ...
(Date:12/22/2014)... LUXEMBOURG , Dec. 22, 2014  ConvaTec, a ... Paul Moraviec has been appointed Interim Chief Executive Officer ... Mr. Moraviec succeeds Ken Berger .  "The Board ... service in leading ConvaTec over the past three years," ... Board of Directors.  "We are confident that the company ...
(Date:12/22/2014)... 22, 2014  Eiger BioPharmaceuticals Incorporated announced the ... lonafarnib in patients with chronic hepatitis delta virus ... National Institutes of Health (NIH) Clinical Center in ... randomized, placebo-controlled, dose ascending study evaluated two doses ... mg twice daily for 28 days.  "This proof-of-concept ...
Breaking Medicine Technology:NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 2NxStage Receives FDA Clearance for Home Nocturnal Hemodialysis 3ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... Oct. 7 MO BIO Laboratories, Inc., ... purification, announces the launch of a groundbreaking new product, ... soil samples upon collection. LifeGuard solution will enable ... RNA degradation or changes in transcript levels during transport ...
... Calif., Oct. 7 Odyssey Thera, Inc. announced that ... investors, Pfizer Inc. following Pfizer,s decision to progress drug ... multi-year alliance with Pfizer announced in August, 2006. These ... earned for the advancement of specific drug candidates, and ...
Cached Medicine Technology:MO BIO Laboratories, Inc. Launches LifeGuard(TM) Soil Preservation Solution 2
(Date:12/22/2014)... (PRWEB) December 22, 2014 Christmas is days ... has a fast and easy solution that will please: the ... can be purchased from from $25 up to $350," says ... 100% customer satisfaction and a wide array of skin care ... fees and no expiration dates. , Gift delivery past ...
(Date:12/22/2014)... OAK BROOK, Ill. (PRWEB) December 21, 2014 ... receive radiologist recommendations for chest computed tomography (CT) ... have clinically relevant findings, including cancer, according to ... Radiology. , Researchers said the findings show ... chest X-rays represent valuable contributions to patient care. ...
(Date:12/22/2014)... Phoenix, AZ (PRWEB) December 22, 2014 ... for the absolute best in Arizona home contracting services ... with regard to its quality services in 2014. As ... area since the early 1970s, Parker and Sons is ... ongoing reliability. The company works side-by-side with other top ...
(Date:12/21/2014)... 2014 Weddingshe.com, an outstanding online supplier ... recently released its new selection of Cocktail Dresses for ... according to the newest fashion trends. , ... for cocktail parties . All of them are offered ... We are making every effort to offer a nice ...
(Date:12/21/2014)... Coral Gables, FL (PRWEB) December 21, 2014 ... of head lice, who do they call? The new answer ... Leon Blvd, Coral Gables FL 33134, their newest treatment center ... eradicate this pest quickly, conveniently and without the use of ... Grand Opening is scheduled for January 1, 2015. Like the ...
Breaking Medicine News(10 mins):Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 2Health News:RSNA: Radiologist Recommendations for Chest CT Have High Clinical Yield 3Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 2Health News:Parker & Sons Reports A Record Number Of Favorable References With Regard To Its Quality Services In 2014 3Health News:Stunning Cocktail Party Dresses from Weddingshe.com 2Health News:All-Natural Florida Lice Removal Company Opens New Lice Treatment Salon In South Florida 2
... researcher has discovered an association between foie gras prepared ... amyloid found in rheumatoid arthritis or tuberculosis. ,Dr. ... Tennessee Graduate School of Medicine in Knoxville, says that ... first evidence that a food product can hasten amyloid ...
... PLoS Medicine shows that men can help avoid fractures ... fractures are common among older people and can have devastating ... recommended that women should take exercise to reduce the ... with age is known as osteoporosis. Women are at particular ...
... antigen (PSA) testing continues to be problematic. Even though ... reduce death, illness or disability from prostate cancer, testing ... ,A recent nation-wide survey indicates almost half of Canadian ... lifetime. In this review, Drs. Ian Thompson and Donna ...
... government Tuesday enforced a ban on the use of plastic ... heavy rains the day before flooded Guwahati, throwing the ... ,"The decision to ban the use of plastic and polythene ... logging. The ban would be enforced very strictly and there ...
... medication administered to heart attack or stroke victims to ... reduce the risk of amputation, according to a study ... of critical care has grown significantly in the ... for combating frostbite, say the authors of the article ...
... support film/television actress Fran Drescher's cancer organisation . The ... her Cancer Schmancer organisation. ,'Angelina is supporting ... Jolie's mum actress Marcheline Bertrand fought a cancer battle ... ,Drescher, a cancer survivor, whose disease was diagnosed at ...
Cached Medicine News:Health News:Scientists Establish Link Between Foie Gras and Disease 2Health News:Exercise Reduces Fracture in Men 2Health News:Frostbite can Be Treated by Bloodclot Drug 2
... (gadopentetate dimeglumine) injection was introduced in 1988, ... contrast-enhanced magnetic resonance imaging (MRI). It became ... in MRI. Today, the product is still ... head, neck and body. MAGNEVIST is used ...
... injection is a nonionic, iodinated, low-osmolar ... Introduced in the U.S. in 1995, ... Europe, ULTRAVIST today is used ... established a positive clinical experience in ...
The Pinn-ACL Guide can be used to create tibial tunnels of known lengths with a variable angle adjustment of 35 to 60 degrees with the use of a,graduated pin-sleeve....
Forceps with round handle, straight...
Medicine Products: